このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Lupin 将来の成長

Future 基準チェック /26

Lupin利益と収益がそれぞれ年間18.2%と8.5%増加すると予測されています。EPS は年間増加すると予想されています。自己資本利益率は 3 年後に16.2% 18%なると予測されています。

主要情報

18.4%

収益成長率

18.3%

EPS成長率

Pharmaceuticals 収益成長	17.1%
収益成長率	8.4%
将来の株主資本利益率	16.4%
アナリストカバレッジ	Good
最終更新日	21 Jun 2024

今後の成長に関する最新情報

Analysts Are Updating Their Lupin Limited (NSE:LUPIN) Estimates After Its Annual Results

May 09

Earnings Beat: Lupin Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Feb 10

Recent updates

These 4 Measures Indicate That Lupin (NSE:LUPIN) Is Using Debt Safely

Jun 15

Analysts Are Updating Their Lupin Limited (NSE:LUPIN) Estimates After Its Annual Results

May 09

Earnings Beat: Lupin Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Feb 10

Lupin Limited's (NSE:LUPIN) Share Price Could Signal Some Risk

Jan 19

Is Lupin (NSE:LUPIN) Using Too Much Debt?

Nov 10

Is Lupin (NSE:LUPIN) Using Too Much Debt?

Jun 23

Here's Why Lupin (NSE:LUPIN) Can Manage Its Debt Responsibly

Mar 24

Lupin's (NSE:LUPIN) Dividend Is Being Reduced To ₹4.00

Jul 08

Is Lupin Limited (NSE:LUPIN) Worth ₹756 Based On Its Intrinsic Value?

Mar 27

Lupin (NSE:LUPIN) Could Easily Take On More Debt

Jan 22

業績と収益の成長予測

NSEI:LUPIN - アナリストの将来予測と過去の財務データ ( )INR Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
3/31/2027	256,641	33,675	29,596	40,818	13
3/31/2026	238,884	29,013	24,532	34,235	33
3/31/2025	216,792	24,091	19,391	28,153	34
3/31/2024	200,108	19,145	27,195	36,484	N/A
12/31/2023	194,801	17,910	N/A	N/A	N/A
9/30/2023	186,049	13,314	18,582	34,087	N/A
6/30/2023	177,119	9,714	N/A	N/A	N/A
3/31/2023	166,417	4,301	3,976	18,972	N/A
12/31/2022	160,946	-3,239	N/A	N/A	N/A
9/30/2022	159,333	682	-19,299	-9,456	N/A
6/30/2022	158,791	-21,596	N/A	N/A	N/A
3/31/2022	164,055	-15,280	-5,378	3,673	N/A
12/31/2021	163,052	-5,497	N/A	N/A	N/A
9/30/2021	161,616	-6,570	22,007	29,207	N/A
6/30/2021	159,053	16,521	N/A	N/A	N/A
3/31/2021	151,630	12,165	11,441	18,218	N/A
12/31/2020	152,260	11,458	N/A	N/A	N/A
9/30/2020	149,777	-1,609	-4,671	523	N/A
6/30/2020	150,249	-5,572	N/A	N/A	N/A
3/31/2020	153,748	-3,995	7,957	14,688	N/A
12/31/2019	174,693	-4,428	N/A	N/A	N/A
9/30/2019	176,892	3,138	21,219	29,124	N/A
6/30/2019	172,806	7,068	N/A	N/A	N/A
3/31/2019	146,646	5,121	6,806	16,660	N/A
12/31/2018	163,114	-4,665	N/A	N/A	N/A
9/30/2018	157,822	-931	N/A	N/A	N/A
6/30/2018	157,829	960	N/A	N/A	N/A
3/31/2018	157,765	2,513	1,978	17,512	N/A
12/31/2017	159,233	14,150	N/A	N/A	N/A
9/30/2017	164,306	18,264	N/A	N/A	N/A
6/30/2017	167,693	20,336	N/A	N/A	N/A
3/31/2017	173,674	25,575	N/A	41,135	N/A
12/31/2016	173,910	29,351	N/A	N/A	N/A
9/30/2016	164,558	28,265	N/A	N/A	N/A
6/30/2016	154,918	25,841	N/A	N/A	N/A
3/31/2016	141,316	22,607	N/A	-3,824	N/A
12/31/2015	131,055	20,106	N/A	N/A	N/A
9/30/2015	127,273	20,823	N/A	N/A	N/A
6/30/2015	125,794	23,035	N/A	N/A	N/A
3/31/2015	127,700	24,032	N/A	27,331	N/A
12/31/2014	128,124	24,092	N/A	N/A	N/A
9/30/2014	126,567	22,839	N/A	N/A	N/A
6/30/2014	121,512	20,601	N/A	N/A	N/A
3/31/2014	112,866	18,364	N/A	20,039	N/A
12/31/2013	107,519	16,915	N/A	N/A	N/A
9/30/2013	102,309	15,506	N/A	N/A	N/A
6/30/2013	98,637	14,348	N/A	N/A	N/A

アナリストによる今後の成長予測

収入対貯蓄率: LUPINの予測収益成長率 (年間18.2% ) は貯蓄率 ( 6.7% ) を上回っています。

収益対市場: LUPINの収益 ( 18.2% ) はIndian市場 ( 16% ) よりも速いペースで成長すると予測されています。

高成長収益: LUPINの収益は増加すると予測されていますが、大幅には増加しません。

収益対市場: LUPINの収益 ( 8.5% ) Indian市場 ( 9.6% ) よりも低い成長が予測されています。

高い収益成長: LUPINの収益 ( 8.5% ) 20%よりも低い成長が予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: LUPINの自己資本利益率は、3年後には低くなると予測されています ( 16.2 %)。

Lupin 将来の成長

Future 基準チェック /26

主要情報

今後の成長に関する最新情報

Analysts Are Updating Their Lupin Limited (NSE:LUPIN) Estimates After Its Annual Results

Earnings Beat: Lupin Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Price target increased by 12% to ₹1,355

Price target increased by 8.2% to ₹1,067

Price target increased by 15% to ₹878

Price target decreased to ₹774

Recent updates

These 4 Measures Indicate That Lupin (NSE:LUPIN) Is Using Debt Safely

Lupin Limited Announces Board Appointments

Analysts Are Updating Their Lupin Limited (NSE:LUPIN) Estimates After Its Annual Results

New minor risk - Dividend sustainability

With EPS Growth And More, Lupin (NSE:LUPIN) Makes An Interesting Case

Full year 2024 earnings: EPS misses analyst expectations

Lupin Limited to Report Q4, 2024 Results on May 06, 2024

Investor Optimism Abounds Lupin Limited (NSE:LUPIN) But Growth Is Lacking

Lupin Limited Announces Change in Management

Here's Why Lupin (NSE:LUPIN) Can Manage Its Debt Responsibly

Lupin Limited Launches Bromfenac Ophthalmic Solution, 0.075% in the United States

Earnings Beat: Lupin Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Price target increased by 12% to ₹1,355

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

Lupin Limited Receives Approval from U.S. FDA for Bromfenac Ophthalmic Solution, 0.075%

Insufficient new directors

Lupin Limited to Report Q3, 2024 Results on Feb 07, 2024

Lupin Receives Approval from U.S. FDA for Febuxostat Tablets

Lupin Limited's (NSE:LUPIN) Share Price Could Signal Some Risk

Lupin Limited Launches Bromfenac Ophthalmic Solution, 0.07% in the United States

Lupin Receives Approval from U.S. FDA for Loteprednol Etabonate Ophthalmic Suspension, 0.2%

Lupin Limited Receives Tentative Approval from U.S. FDA for Canagliflozin Tablets

Lupin Limited Launches First Fixed-Dose Triple Combination Drug, Vilfuro-G® for COPD Management in India

Lupin Limited Receives Tentative Approval from U.S. FDA for Dapagliflozin Tablets

Price target increased by 8.2% to ₹1,067

Is Lupin (NSE:LUPIN) Using Too Much Debt?

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Lupin Limited to Report Q2, 2024 Results on Nov 08, 2023

Lupin Limited Receives Tentative Approval from U.S. FDA for Calcium, Magnesium, Potassium, and Sodium Oxybates Oral Solution

Lupin Limited (BSE:500257) completed the acquisition of Ondero and Ondero - Met from Boehringer Ingelheim International GmbH.

Price target increased by 15% to ₹878

Lupin Limited Approves Dividend for the Year Ended March 31, 2023

Girard Sharp LLP and Motley Rice LLC Announce a Proposed Settlement in re Xyrem (Sodium Oxybate) Antitrust Litigation

Girard Sharp LLP and Motley Rice LLC Announce a Proposed Settlement in In re Xyrem (Sodium Oxybate) Antitrust Litigation

Lupin Limited Receives Tentative Approval from U.S. Fda for Dolutegravir Lamivudine and Tenofovir Alafenamide Tablets

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Lupin Limited Receives EIR from U.S. FDA for its Pithampur Unit-2 Manufacturing Facility

Upcoming dividend of ₹4.00 per share at 0.4% yield

Lupin Limited, Annual General Meeting, Aug 03, 2023

Lupin Limited Receives Approval from U.S. Fda for Cyanocobalamin Nasal Spray

Is Lupin (NSE:LUPIN) Using Too Much Debt?

Lupin Limited Launches Thiamine Hydrochloride Injection USP in the United States

Lupin Launches Darunavir Tablets in the United States

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Here's Why Lupin (NSE:LUPIN) Can Manage Its Debt Responsibly

Third quarter 2023 earnings: Revenues in line with analyst expectations

Lupin Receives Approval from US FDA for Glycopyrrolate Injection, USP

Lupin Limited Receives Tentative Approval from U.S. FDA for Dolutegravir, Emtricitabine and Tenofovir Alafenamide (DETAF) Tablets

Lupin Limited to Report Q3, 2023 Results on Feb 09, 2023

Lupin Limited Launches Sacubitril and Valsartan Combination Drug for Heart Failure Patients

Lupin Receives Tentative Approval from U.S. FDA for Dolutegravir and Rilpivirine Tablets

Lupin and Exeltis Announce Reimbursement Approval of NaMuscla in Spain for the Symptomatic Treatment of Myotonia in Adults with Non-Dystrophic Myotonic Disorders

Lupin Receives Approval from U.S. FDA for Fesoterodine Fumarate Extended-Release Tablets

Lupin Limited Launches Novel Fixed-Dose Triple Drug Combination Difizma® Dpi to Treat Inadequately Controlled Asthma

Lupin Limited Announces Christine Mundkur Steps Down from Board of Directors, Effective January 1, 2023

Lupin Launches Rufinamide Tablets USP in the United States

Lupin Launches Formoterol Fumarate Inhalation Solution in the United States

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Lupin Receives Tentative Approval from U.S. FDA for Doxycycline Capsules

Lupin Limited Receives Tentative Approval from U.S. FDA for Drospirenone Tablets

Lupin Limited Update on its Biotech Manufacturing Facility

Lupin Announces Resignation of Kamal K. Sharma from the Board of Directors

Lupin Limited Appoints Shahin Fesharaki as Global Chief Scientific Officer

Lupin Receives Approval from U.S. FDA for Mirabegron Extended-Release Tablets

Lupin Receives Approval from U.S. FDA for Diclofenac Sodium Topical Solution USP, 2% w/w

Lupin Receives Health Canada Approval for Rymti® (Biosimilar Etanercept)

Lupin Launches Generic Suprep® Bowel Prep Kit in the United States

Lupin Limited in Partnership with Pharmascience Inc. Receives Tentative Approval from U.S. Fda for Dasatinib Tablets

Lupin Limited Announces Launch of Desvenlafaxine Extended-Release Tablets, 25 Mg